Earnings call transcript: Terumo Corp. beats Q4 2025 earnings expectations

Terumo reported a strong Q4/FY2025 beat, with EPS of 17.87 versus 14.92 expected and revenue of 300.32 billion JPY versus 288.1 billion JPY, while operating profit hit a record 176.3 billion JPY and adjusted operating profit reached 219.4 billion JPY. Despite tariff and one-time expense headwinds, the company guided FY2026 revenue up 8% in local currency and operating profit up 20%, and lifted the dividend to 36 JPY per share from 30 JPY. Shares jumped 18.08% in after-hours trading, reflecting confidence in North America demand, OrganOx integration, and sustained margin resilience.

Analysis

This read-through is less about a one-quarter beat than about a de-risking of the medium-term earnings base. The important second-order effect is that tariff and restructuring noise is rolling off into a cleaner 2026 P&L, which should mechanically widen operating leverage even if end-demand merely stays healthy. That makes the stock more “quality compounder” than “cyclical recovery,” and should compress the discount rate investors apply to the multiple.

The competitive takeaway is that the strongest economics are concentrating in categories where Terumo owns both product breadth and procedural workflow, especially neurovascular and organ preservation. That matters because bundled portfolios raise switching costs and make share gains stickier than simple point-product wins; it also means smaller rivals will have to spend more on evidence generation and channel support just to defend installed base. For medtech peers, the bigger threat is not pricing pressure from Terumo alone, but a higher bar for R&D efficiency and M&A discipline.

The main risk is not next quarter execution, but whether external cost shocks persist long enough to offset the cleaner base: tariffs, input inflation, and project delays can still cap margin expansion if they re-accelerate. The market may also be underestimating how much of the 2026 upside is already visible, which creates event-risk after the initial post-earnings rerate. If the next update shows only incremental improvement in the tariff assumption or organic growth deceleration in North America, the stock could give back a meaningful portion of the move despite strong reported fundamentals.

Key Decisions for Investors

• Go long Terumo on pullbacks over the next 1-3 weeks; use the post-earnings rerate to enter only if implied volatility normalizes. Risk/reward favors a 6-12 month hold as cleaner FY26 earnings should drive multiple expansion.
• Pair trade: long Terumo vs short a lower-quality medtech peer with higher tariff/input-cost sensitivity over 3-6 months. The thesis is operating leverage and portfolio breadth winning in a slower growth tape.
• For options, buy 3-6 month call spreads in Terumo rather than outright calls to capture the rerating while limiting downside if the market fades the beat. Best if the stock consolidates after the initial spike.
• Fade overenthusiasm in competitors exposed to the same end markets: treat any strength in smaller neurovascular names as an opportunity to short into better Terumo-led share expectations. Time horizon: 1-2 quarters.
• Set a risk trigger to reduce exposure if management guidance on tariffs or North America demand softens next update; that would likely be the fastest path for the stock to mean-revert.